A case of SARS-CoV-2 reinfection in Ecuador

Prado-Vivar, Belén; Becerra-Wong, Mónica; Guadalupe, Juan José; Márquez, Sully; Gutiérrez, Bernardo; Rojas-Silva, Patricio; Grunauer, Michelle; Trueba, Gabriel; Barragán, Verónica; Cárdenas, Paúl

doi:10.1016/s1473-3099(20)30910-5

Cited by 82 publications

(93 citation statements)

References 8 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We read with interest Belén Prado-Vivar and colleagues' findings of suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection in a 46-year-old man in Ecuador. 1 As reported elsewhere, 2 Prado-Vivar and colleagues describe a more severe symptomatic course during the second infection than during the first. Understanding factors associated with potential reinfection might enable early decision-making for the clinical management of suspected cases.…”

mentioning

confidence: 70%

“…Prado-Vivar and colleagues' patient was IgM-reactive, IgG-negative on a lateral flow assay, with presumably an assigned significance of at least an initial response to SARS-CoV-2. 1 Other reported cases of reinfection have likewise described serology at initial presentation as IgM only, negative, or not tested. 2 Our experience with lateral flow assays suggests that early IgM-only positive results should be interpreted with caution: six of 12 health-care workers tested in a delayed case identification programme 3 underwent retesting with both an anti-nucleocapsid (anti-NP) IgG and an anti-receptor binding domain (anti-RBD) IgG assay and had a seronegative result ( appendix pp 3–4 ).…”

mentioning

confidence: 97%

See 1 more Smart Citation

Structured serological testing is an essential component to investigating SARS-CoV-2 reinfection

Pallett

Jones

Randell

et al. 2021

The Lancet Infectious Diseases

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 70%

mentioning

confidence: 97%

Structured serological testing is an essential component to investigating SARS-CoV-2 reinfection

Pallett

Jones

Randell

et al. 2021

The Lancet Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Three more cases at least 6 months from the first episode are under investigation based on clinical, epidemiological and laboratory data [ 11 ], all leading to a second mild COVID-19; as many other cases reported in the literature, these cases are imperfectly documented. With only few reports in the literature, SARS-CoV-2 reinfection seems to be rare within the first 6 months after COVID-19 [ 1 , 4 , 12 , 13 ]. Based on seasonal coronaviruses immunity, we can expect that reinfection will be increasingly common with longer time intervals since the first SARS-CoV-2 infection, following a progressive decline of protective antibody titers [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical, virologic and immunologic features of a mild case of SARS-CoV-2 reinfection

Vetter¹,

Cordey²,

Schibler³

et al. 2021

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Objectives We report a case of SARS-CoV-2 reinfection 6 months after the first infection in a young healthy female physician. Both episodes led to mild COVID-19. Methods SARS-CoV-2 infections was detected by RT-PCR on naso-pharyngeal specimens. Reinfection was confirmed by whole-genome sequencing. Kinetics of total anti-S receptor binding domain immunoglobulins (Ig anti-S RBD), anti-nucleoprotein (anti-N) and neutralizing antibodies were determined in serial serum samples retrieved during both infection episodes. Memory B cells responses were assessed at day 12 post reinfection. Results Whole-genome sequencing identified two different SARS-CoV-2 genomes both belonging to clade 20A, with only one non-synonymous mutation in the spike protein, and clustered with viruses circulating in Geneva (Switzerland) at the time of each of the corresponding episodes. Seroconversion was documented with low level of total Ig anti-S RBD and anti-N antibodies at one month after the first infection whereas neutralizing antibodies quickly declined after the first episode and then were boosted by the reinfection, with high titers detectable 4 days after symptoms onset. A strong memory B cell response was detected at day 12 post onset of symptoms during reinfection, indicating that the first episode elicited cellular memory responses. Conclusion Rapid decline of neutralizing antibodies may put medical personnel at risk of reinfection as shown in this case. Reinfection however leads to a significant boosting of previous immune responses. Larger cohorts of reinfected subjects with detailed descriptions of their immune responses are needed to define correlates of protection and their duration after infection.

show abstract

“…A recent review of the literature [ 11 ] analyzed 16 reported cases of reinfection confirmed by sequencing, 10 of which were in pre-print [ 2 , 10 , [12] , [13] , [14] , [15] , [16] , [17] , [18] ]. Among the 16 described cases, the median duration between the first and second infection was 66 with a range of 19-142 days [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

Re-infection of SARS-CoV-2: A case in a young dental healthcare worker

Fageeh¹,

Alshehri²,

Fageeh³

et al. 2021

Journal of Infection and Public Health

View full text Add to dashboard Cite

Reinfection with SARS-CoV-2 is a rare phenomenon. To date, there has been some cases reported from countries such as United States, Ecuador, Hong Kong, the Netherlands and Belgium. This case report presents the first case of reinfection from Saudi Arabia, and probably the first dental student to have been re-infected with COVID-19. A 24-year-old male dental student presents with reinfection after a period of three months since he was first infected with COVID-19. The signs and symptoms reported by the patient were similar in both instances, except that he developed fever only at the time of reinfection. The infection and reinfection were confirmed with a RT-PCR test reports. This report highlights how it is necessary to continue to observe all the prescriptions recently indicated in the literature in order to avoid new contagion for all health workers after healed from covid-19 or asymptomatic positive, since as seen sometimes the infection does not ensures complete immunity in 100% of cases.

show abstract

A case of SARS-CoV-2 reinfection in Ecuador

Cited by 82 publications

References 8 publications

Structured serological testing is an essential component to investigating SARS-CoV-2 reinfection

Structured serological testing is an essential component to investigating SARS-CoV-2 reinfection

Clinical, virologic and immunologic features of a mild case of SARS-CoV-2 reinfection

Re-infection of SARS-CoV-2: A case in a young dental healthcare worker

Contact Info

Product

Resources

About